Literature DB >> 31189791

Combination of Commonly Examined Parameters Is a Useful Predictor of Positive 99 mTc-Labeled Pyrophosphate Scintigraphy Findings in Elderly Patients With Suspected Transthyretin Cardiac Amyloidosis.

Kyohei Marume1, Seiji Takashio1, Masato Nishi1, Kyoko Hirakawa1, Masahiro Yamamoto1, Shinsuke Hanatani1, Seitaro Oda2, Daisuke Utsunomiya2, Shinya Shiraishi2, Mitsuharu Ueda3, Taro Yamashita3, Kenji Sakamoto1, Eiichiro Yamamoto1, Koichi Kaikita1, Yasuhiro Izumiya4, Yasuyuki Yamashita2, Yukio Ando3, Kenichi Tsujita1.   

Abstract

BACKGROUND: A recent study revealed a high prevalence of transthyretin (TTR) cardiac amyloidosis (CA) in elderly patients. 99 mTc-labeled pyrophosphate (99 mTc-PYP) scintigraphy is a remarkably sensitive and specific modality for TTR-CA, but is only available in specialist centres; thus, it is important to raise the pretest probability. The aim of this study was to evaluate the characteristics of patients with 99 mTc-PYP positivity and make recommendations about patient selection for 99 mTc-PYP scintigraphy.Methods and 
Results: We examined 181 consecutive patients aged ≥70 years who underwent 99 mTc-PYP scintigraphy at Kumamoto University Hospital between January 2012 and December 2018. Logistic regression analyses showed that high-sensitivity cardiac troponin T (hs-cTnT) ≥0.0308 ng/mL, left ventricular posterior wall thickness ≥13.6 mm, and wide QRS (QRS ≥120 ms) were strongly associated with 99 mTc-PYP positivity. We developed a new index for predicting 99 mTc-PYP positivity by adding 1 point for each of the 3 factors. The 99 mTc-PYP positive rate increased by a factor of 4.57 for each 1-point increase (P<0.001). Zero points corresponded to a negative predictive value of 87% and 3 points corresponded to a positive predictive value of 96% for 99 mTc-PYP positivity.
CONCLUSIONS: The combination of biochemical (hs-cTnT), physiological (wide QRS), and structural (left ventricular posterior wall thickness) findings can raise the pretest probability for 99 mTc-PYP scintigraphy. It can assist clinicians in determining management strategies for elderly patients with suspected CA.

Entities:  

Keywords:  99 mTc-labeled pyrophosphate scintigraphy; Cardiac amyloidosis; Diagnosis; Transthyretin

Mesh:

Substances:

Year:  2019        PMID: 31189791     DOI: 10.1253/circj.CJ-19-0255

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  6 in total

Review 1.  Multidisciplinary Approaches for Transthyretin Amyloidosis.

Authors:  Haruki Koike; Takahiro Okumura; Toyoaki Murohara; Masahisa Katsuno
Journal:  Cardiol Ther       Date:  2021-06-04

Review 2.  How to Identify Transthyretin Cardiac Amyloidosis at an Early Stage.

Authors:  Yasuhiro Izumiya; Hiroya Hayashi; Hirotoshi Ishikawa; Atsushi Shibata; Minoru Yoshiyama
Journal:  Intern Med       Date:  2020-07-21       Impact factor: 1.271

Review 3.  99m Technetium-pyrophosphate scintigraphy: a practical guide for early diagnosis of transthyretin amyloid cardiomyopathy.

Authors:  Nobuhiro Tahara; Olivier Lairez; Jin Endo; Atsushi Okada; Mitsuharu Ueda; Tomonori Ishii; Yoshinobu Kitano; Hahn-Ey Lee; Eleonora Russo; Toru Kubo
Journal:  ESC Heart Fail       Date:  2021-11-29

Review 4.  Clinical recommendations to diagnose and monitor patients with transthyretin amyloid cardiomyopathy in Asia.

Authors:  Weiqin Lin; Pairoj Chattranukulchai; Alex Pw Lee; Yen-Hung Lin; Wen-Chung Yu; Houng-Bang Liew; Abraham Oomman
Journal:  Clin Cardiol       Date:  2022-07-06       Impact factor: 3.287

5.  Diagnosing Transthyretin Cardiac Amyloidosis by Technetium Tc 99m Pyrophosphate: A Test in Evolution.

Authors:  Timothy J Poterucha; Pierre Elias; Sabahat Bokhari; Andrew J Einstein; Albert DeLuca; Mona Kinkhabwala; Lynne L Johnson; Kathleen R Flaherty; Sunil E Saith; Jan M Griffin; Adler Perotte; Mathew S Maurer
Journal:  JACC Cardiovasc Imaging       Date:  2020-11-18

6.  Clinical characteristics and natural history of wild-type transthyretin amyloid cardiomyopathy in Japan.

Authors:  Toshihiro Yamada; Seiji Takashio; Yuichiro Arima; Masato Nishi; Mami Morioka; Kyoko Hirakawa; Shinsuke Hanatani; Koichiro Fujisue; Kenshi Yamanaga; Hisanori Kanazawa; Daisuke Sueta; Satoshi Araki; Hiroki Usuku; Taishi Nakamura; Satoru Suzuki; Eiichiro Yamamoto; Mitsuharu Ueda; Koichi Kaikita; Kenichi Tsujita
Journal:  ESC Heart Fail       Date:  2020-07-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.